Part 3: Risk-based Quality Management Video (RBQM) Series

ICH Q9 (1) focuses on Quality Risk Management. Revisions may influence how we apply and perform risk management in clinical trials. In part three of our RBQM video series, Amy Kissam-Sands and Tim Audin, Senior Director, Global Biometrics Group Lead talk with Taren Grom, Editor, PharmaVOICE about the specific areas they expect ICH Q9 (1) to focus on.

Return to Insights Center

Related Insights

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Article

Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct

Sep 14, 2021

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Video

How to transition existing trials under EU-CTR

Feb 1, 2023

Article

Decentralized trial tools and technologies are here to stay: A regulatory perspective

Jul 23, 2021

Article

How a joined-up development strategy pays off for early-stage biotechs

May 19, 2021

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Blog

Optimize your CMC strategy: Five steps to avoid regulatory setbacks

May 15, 2025

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Playbook

Insights from the 2022 R&D Innovation Survey

Feb 17, 2023

Related Insights

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Article

Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct

Sep 14, 2021

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Video

How to transition existing trials under EU-CTR

Feb 1, 2023

Article

Decentralized trial tools and technologies are here to stay: A regulatory perspective

Jul 23, 2021

Show more